BeiGene’s EGFR/cMET ADC initiates Phase I Clinical Trial in the U.S.
BeOne
Developer of Molecular Targeted and Immune Anti-Tumor Drugs
On September 18, 2025, BeiGene registered a U.S. Phase I clinical trial of BG-C0902 (as monotherapy or in combination) for advanced solid tumors on the ClinicalTrials.gov website.
According to the clinical trial registration information, BG-C0902 is an EGFR/cMET dual-target ADC with a TOP1 inhibitor (TOP1i) as its payload. This Phase I clinical trial plans to enroll 63 patients with advanced solid tumors, and is expected to conclude in November 2027.
According to the information disclosed by BeiGene at its R&D Day, ADCs are a key focus area in its pipeline layout—and the company has also prioritized the development of bispecific and trispecific antibody-based ADCs. In fact, BG-C0902 is an EGFR/cMET/cMET trispecific ADC, and it also marks BeiGene’s first dual-target ADC to enter the clinical stage.
Source: Armstrong